1-Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis1999;34(5):795–808.
2-Beladi Musavi SS, Hayati F, Talebnejad M, Mousavi M. What is the difference between causes of ESRD in Iran and developing countries? Shiraz E-Med J [Serial Online] 2012;13(2). Available from: URL:
http://semj.sums.ac.ir/vol13/apr2012/90016.htm. Accessed on month day, year.
3-Beladi Musavi SS, Hayati F, Alemzadeh Ansari MJ, Valavi E, Cheraghian B, Shahbazian HA, et al. Survival at 1, 3, and 5 Years in Diabetic and Nondiabetic Hemodialysis Patients. Iran J Kidney Dis 2010;4(1):74-7.
4-Perneger TV, Brancati FL, Whelton PK, Klag MJ. End-stage renal disease attributable to diabetes mellitus. Ann Intern Med 1994;121(12):912-8.
6-Beladi Musavi SS, Sametzadeh M, Hayati F, Fatemi SM. Evaluation of acquired cystic kidney disease in patients on hemodialysis with ultrasonography. Iran J Kidney Dis 2010;4(3):223-6.
7-Van Dijk PC, Jager KJ, Stengel B,
Grönhagen-Riska C,
Feest TG,
Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 2005;67(4):1489-99.
8-Haghighi AN, Broumand B, D'Amico M, Locatelli F, Ritz E. The epidemiology of end-stage renal disease in Iran in an international perspective. Nephrol Dial Transplant 2002;17(1):28-32.
9-Malekmakan L, Haghpanah S, Pakfetrat M, Malekmakan A, Khajehdehi P. Causes of chronic renal failure among Iranian hemodialysis patients. Saudi J Kidney Dis Transpl 2009;20(3):501-4.
10-Aghighi M, Mahdavi-Mazdeh M, Zamyadi M, Heidary Rouchi AR, Rajolani H, Nourozi S. Changing epidemiology of end-stage renal disease in last 10 years in Iran. Iran J Kidney Dis 2009;3(4):192-6.
12-Beladi Musavi SS. Cause of primary nephrotic syndrome in adult patients in Khuzestan province. Abstract book of the 12th International Congress of Nephrology, Dialysis and Transplantation, Iran J Kidney Dis 2009;3:75.
14-Beladi Musavi SS, Hayati F, Shahbazian H. [Is the prevalence of focal and segmental glomerulosclerosis increasing in the Province of Khuzestan?] Jundishapur Sci Med J 2012;11(2):157-62. [In Persian]
26-Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998;32(1):72-9.
27-Chitalia VC, Wells JE, Robson RA,
Searle M,
Lynn KL. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int 1999;56(6):2236-42.
28-Banfi G, Moriggi M, Sabadini E,
Fellin G,
D'Amico G,
Ponticelli C. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 1991;36(2):53-9.
29-Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004;15(8):2169-77.
30-Nash MA, Greifer I, Olbing H,
Bernstein J,
Bennett B,
Spitzer A. The significance of focal sclerotic lesions of glomeruli in children. J Pediatr 1976;88(5):806-13.
31-Ponticelli C, Villa M, Banfi G,
Cesana B,
Pozzi C,
Pani A, et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 1999;34(4):618-25.
32-Troyanov S, Wall CA, Miller JA,
Scholey JW,
Cattran DC. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005;16(4):1061-8.
33-Thomas DB, Franceschini N, Hogan SL,
Ten Holder S,
Jennette CE,
Falk RJ, et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006;69(5):920-6.
34-Beaman M, Howie AJ, Hardwicke J,
Michael J,
Adu D. The glomerular tip lesion: a steroid responsive nephrotic syndrome. Clin Nephrol 1987;27(5):217-21.
35-Winn MP, Conlon PJ, Lynn KL,
Howell DN,
Slotterbeck BD,
Smith AH, et al. Linkage of a gene causing familial focal segmental glomerulosclerosis to chromosome 11 and further evidence of genetic heterogeneity. Genomics 1999;58(2):113-20.
36-Pollak MR. The genetic basis of FSGS and steroid-resistant nephrosis. Semin Nephrol 2003;23(2):141-6.
37-Ruf RG, Lichtenberger A, Karle SM,
Haas JP,
Anacleto FE,
Schultheiss M, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004;15(3):722-32.
38-Heering P, Braun N, Müllejans R,
Ivens K,
Zäuner I,
Fünfstück R, et al. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis 2004;43(1):10-8.
39-Ponticelli C, Rizzoni G, Edefonti A,
Altieri P,
Rivolta E,
Rinaldi S, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993;43(6):1377-84.
40-Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr 1994;125(6 Pt1):981-6.
41-Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 1996;7(1):56-63.
42-Duncan N, Dhaygude A, Owen J,
Cairns TD,
Griffith M,
McLean AG, et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 2004;19(12):3062-7.
43-Segarra A, Vila J, Pou L,
Arbós A,
Quiles T,
Piera LL. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 2002;17(4):655-62.
44-Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol 2004;19(3):281-7.
45-Li X, Li H, Ye H,
Li Q,
He X,
Zhang X, et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis 2009;54(1):51-8.
46-Gipson DS, Trachtman H, Kaskel FJ,
Greene TH,
Radeva MK,
Gassman JJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011;80(8):868-78.
47-Choi MJ, Eustace JA, Gimenez LF,
Atta MG,
Scheel PJ,
Sothinathan R, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61(3):1098-114.
48-Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D. Mycophenolatemofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002;17(11):2011-3.
49-Montané B, Abitbol C, Chandar J,
Strauss J,
Zilleruelo G. Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 2003;18(8):772-7.
50-Cattran DC, Wang MM, Appel G,
Matalon A,
Briggs W. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004;62(6):405-11.
51-Deegens JK, Wetzels JF. Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial. Kidney Int 2011;80(8):798-801.
52-Siegel NJ, Gaudio KM, Krassner LS,
McDonald BM,
Anderson FP,
Kashgarian M. Steroid-dependent nephrotic syndrome in children: histopathology and relapses after cyclophosphamide treatment. Kidney Int 1981;19(3):454-9.
53-Schulman SL, Kaiser BA, Polinsky MS,
Srinivasan R,
Baluarte HJ. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr 1988;113(6):996-1001.
54-Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie. Arch Dis Child 1987;62(11):1102-6.
55-Tumlin JA, Miller D, Near M,
Selvaraj S,
Hennigar R,
Guasch A. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2006;1(1):109-16.
56-Cho M, Hurley JK, Kopp JB. Sirolimus for focal segmental glomerulosclerosis is associated with nephrotoxicity.
Am J Kidney Dis. 2007;49(2):310-7
57-Cho ME, Hurley JK, Kopp JB. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis 2007;49(2):310-7.
58-Fervenza FC, Fitzpatrick PM, Mertz J,
Erickson SB,
Liggett S,
Popham S, et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 2004;19(5):1288-92.
59-Ginsburg DS, Dau P. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis. Clin Nephrol 1997;48(5):282-7.
60-Mitwalli AH. Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis? Nephrol Dial Transplant 1998;13(6):1524-8.
61-Feld SM, Figueroa P, Savin V,
Nast CC,
Sharma R,
Sharma M, et al. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis 1998;32(2):230-7.
62-Godfrin Y, Dantal J, Bouhours JF,
Heslan JM,
Soulillou JP. A new method of measuring albumin permeability in isolated glomeruli. Kidney Int 1996;50(4):1352-7.
)